Ingredients: Water, hydrolyzed soy protein, ethylhexyl palmitate, squalane, cetyl alcohol, nannochloropsis oculata extract (with pullulan, aqua, phenoxyethanol, and sodium benzoate potassium sorbate), stearic acid, glyceryl stearate, PEG-100 stearate, dimethyl MEA (DMAE), Copper Tripeptide-1 (GHK-Cu), PPG 2 myristyl ether, propionate, phenoxyethanol, C10-30 cholesterol/lanosterol esters, lavandula angustifolia (lavender) oil, polysorbate 80, allantoin, leucine, glycine, aloe barbadensis (aloe vera) powder, vitamin E TPGS (tocophersolan), vitamin E (as d-alpha tocopherol plus mixed tocopherols: d-beta, d-delta and d-gamma tocopherol), ubiquinone (CoQ-10), xanthophyll (Lutein) 0 Reviews 0 Reviews Write a Review Write a Review GHK LUXE Eye Cream (Bonus) Write a Review GHK LUXE Eye Cream (Bonus) Additional Info & Ingredients Additional Info & Ingredients PRODUCT DETAILS: Paraben Free
In the animals sacrificed seven days after implantation, those treated with all three doses of sucralfate and those treated with the highest dose of NaBPC157 (50 g) were significantly different in comparison with the control group
Potential Benefits Investigated for gastrointestinal mucosal healing: promoting repair of damaged gut lining in inflammatory bowel conditions, ulcers, and leaky gut Gastric acid stability: uniquely suited for oral delivery among therapeutic peptides because BPC-157 is a native component of gastric juice and resists acid degradation VEGF-mediated angiogenesis: promoting mucosal blood vessel formation essential for tissue repair in chronically inflamed or damaged gut tissue Investigated for inflammatory bowel disease (IBD): preclinical evidence for mucosal protection and anti-inflammatory effects in colitis models Gastroparesis support: pro-motility effects via vagal cholinergic pathways investigated in preclinical models of delayed gastric emptying Leaky gut (intestinal hyperpermeability): tight junction protein support and mucosal integrity restoration investigated in preclinical research Oral route delivers medication directly to the gut mucosa where it is most needed, without requiring injection Convenient capsule administration for daily GI protocols, suitable for patients who cannot or prefer not to self-inject Systemic tissue repair support via potential mucosal absorption at therapeutic doses (extent of systemic absorption is under investigation) May complement injectable BPC-157 protocols for patients with both GI and systemic recovery goals Speak with a physician Interested in BPC-157 (Oral)
Zhong Z, Wen Z, Darnell JE Jr
Then, further studies are warranted to explore whether MSCs derived from other types of tissues, e.g., adipose, umbilical cord, and dental pulp, etc., could convert into Schwann-like cells when they were encapsulated in methacrylated 3D-collagen hydrogel and cultured under the same conditions as GMSCs
